Replies to post #138463 on Biotech Values

[mcbio]

I heard that JNJ's Cowen session that listed TMC435 as one out of six important growth drivers in pipeline.

Good to hear. Thanks for that.

We feel very good about 435, which will be a complementary product.

"Complementary" seems a bit of an understatement to me, but I am of course biased. ; )

[biomaven0]

> TMC435

The panel at Cowen pointed to TMC435 as the drug in this class to watch, with something from Merck (forget the designation) as the runner-up.

Peter

[DewDiligence]

Medivir announces two new phase-3 trials for TMC435:

http://finance.yahoo.com/news/medivir-announces-studies-phase-iii-073000040.html

One trial is a head-to-head of TMC435 vs Incivek (both arms using IFN + ribavirin) in the second-line genotype-1 setting for prior null responders and relapsers.

The other trial is a small single-arm study of TMC435 + IFN + ribavirin in first- and second-line genotype-4 patients.